Biosimilar infiximab CPT-13 for infammatory bowel disease in a real clinical setting: pharmacokinetic outcomes, immunogenicity, and drug survival
Revista española de enfermedades digestivas, 2021-11, Vol.113 (11), p.770 [Peer Reviewed Journal]COPYRIGHT 2021 Sociedad Espanola de Patologia Digestivas ;ISSN: 1130-0108 ;DOI: 10.17235/reed.2021.7638/2020
Full text available
|
||||
 |
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY |  |
(84-028) 37 755 057 | Feedback |
| 19 Nguyen Huu Tho St. Dist.7, HCM |  |
thuvien@tdtu.edu.vn | ||